{"id":46040,"date":"2026-02-19T03:39:16","date_gmt":"2026-02-19T03:39:16","guid":{"rendered":"https:\/\/www.globalresearch.co.kr\/insight\/advanced-therapy-medicinal-products-atmp-cdmo-market-mordor\/"},"modified":"2026-09-25T12:38:40","modified_gmt":"2026-09-25T03:38:40","slug":"advanced-therapy-medicinal-products-atmp-cdmo-market-mordor","status":"publish","type":"post","link":"https:\/\/www.globalresearch.co.kr\/insight\/advanced-therapy-medicinal-products-atmp-cdmo-market-mordor\/","title":{"rendered":"\uc138\uacc4\uc758 \ucca8\ub2e8\ubc14\uc774\uc624\uc758\uc57d\ud488 (ATMP) CDMO \uc2dc\uc7a5 \uaddc\ubaa8\u00b7\uc810\uc720\uc728 \ubd84\uc11d &#8211; \uc131\uc7a5 \ub3d9\ud5a5 \ubc0f \uc804\ub9dd (2026-2031)"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/www.globalresearch.co.kr\/insight\/wp-content\/uploads\/2026\/02\/advanced-therapy-medicinal-products-atmp-cdmo-market_1697186378646_ATMP_CDMO_Key_Players.webp\" alt=\"Chart\" class=\"aligncenter size-full\" \/><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.globalresearch.co.kr\/insight\/wp-content\/uploads\/2026\/02\/advanced-therapy-medicinal-products-atmp-cdmo-market-size-image-1770725735991.webp\" alt=\"Chart\" class=\"aligncenter size-full\" \/><\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-0\">1. \uc11c\ub860<\/p>\n<ul>\n<li class=\"toc-level-2\">1.1 \uc5f0\uad6c \uac00\uc815 \ubc0f \uc2dc\uc7a5 \uc815\uc758<\/li>\n<li class=\"toc-level-2\">1.2 \uc5f0\uad6c \ubc94\uc704<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-1\">2. \uc5f0\uad6c \ubc29\ubc95\ub860<\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-2\">3. \uc694\uc57d<\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-3\">4. \uc2dc\uc7a5 \ud658\uacbd<\/p>\n<ul>\n<li class=\"toc-level-2\">4.1 \uc2dc\uc7a5 \uac1c\uc694<\/li>\n<li class=\"toc-level-2\">4.2 \uc2dc\uc7a5 \ub3d9\uc778\n<ul>\n<li class=\"toc-level-3\">4.2.1 \uc2b9\uc778\ub41c \uc138\ud3ec \ubc0f \uc720\uc804\uc790 \uce58\ub8cc\uc81c\uc758 \uae09\uc18d\ud55c \ud655\uc7a5<\/li>\n<li class=\"toc-level-3\">4.2.2 \uc911\uc18c \ubc14\uc774\uc624\ud14d \uc2a4\ud3f0\uc11c\uc758 \uc544\uc6c3\uc18c\uc2f1 \ucd94\uc138<\/li>\n<li class=\"toc-level-3\">4.2.3 \ubc14\uc774\ub7ec\uc2a4 \ubca1\ud130 \uc81c\uc870 \uc5ed\ub7c9\uc5d0 \ub300\ud55c \ud22c\uc790 \ud655\ub300<\/li>\n<li class=\"toc-level-3\">4.2.4 \ud3d0\uc1c4\ud615 \ubaa8\ub4c8\uc2dd \uc81c\uc870 \uc2a4\uc704\ud2b8 \ucc44\ud0dd<\/li>\n<li class=\"toc-level-3\">4.2.5 \uc0dd\ubb3c\uacf5\uc815 \ucd5c\uc801\ud654\ub97c \uc704\ud55c \ub514\uc9c0\ud138 \ud2b8\uc708 \ud50c\ub7ab\ud3fc<\/li>\n<li class=\"toc-level-3\">4.2.6 \uc815\ub9e5-\uc815\ub9e5 \uc2dc\uac04 \ub2e8\ucd95\uc744 \uc704\ud55c \uacf5\uae09\ub9dd \uc9c0\uc5ed\ud654<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">4.3 \uc2dc\uc7a5 \uc81c\uc57d\n<ul>\n<li class=\"toc-level-3\">4.3.1 \uc219\ub828\ub41c \ucca8\ub2e8 \uce58\ub8cc \uc778\ub825\uc758 \ub9cc\uc131 \ubd80\uc871<\/li>\n<li class=\"toc-level-3\">4.3.2 GMP \uc900\uc218 \uc2dc\uc124\uc5d0 \ub300\ud55c \ub192\uc740 \uc790\ubcf8 \uc9c0\ucd9c<\/li>\n<li class=\"toc-level-3\">4.3.3 GMP \ub4f1\uae09 \ud50c\ub77c\uc2a4\ubbf8\ub4dc \ucd9c\ubc1c \ubb3c\uc9c8\uc758 \uc81c\ud55c\ub41c \uacf5\uae09<\/li>\n<li class=\"toc-level-3\">4.3.4 \uad6d\uacbd \uac04 \ubca1\ud130 \uacf5\uae09\uc5d0 \ub300\ud55c \uc9c0\uc815\ud559\uc801 \uac10\uc2dc \uac15\ud654<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">4.4 \uac00\uce58 \/ \uacf5\uae09\ub9dd \ubd84\uc11d<\/li>\n<li class=\"toc-level-2\">4.5 \uaddc\uc81c \ud658\uacbd<\/li>\n<li class=\"toc-level-2\">4.6 \uae30\uc220 \uc804\ub9dd<\/li>\n<li class=\"toc-level-2\">4.7 \ud3ec\ud130\uc758 5\uac00\uc9c0 \uacbd\uc7c1 \uc694\uc778 \ubd84\uc11d\n<ul>\n<li class=\"toc-level-3\">4.7.1 \uc2e0\uaddc \uc9c4\uc785\uc790\uc758 \uc704\ud611<\/li>\n<li class=\"toc-level-3\">4.7.2 \uacf5\uae09\uc5c5\uccb4\uc758 \uad50\uc12d\ub825<\/li>\n<li class=\"toc-level-3\">4.7.3 \uad6c\ub9e4\uc790\uc758 \uad50\uc12d\ub825<\/li>\n<li class=\"toc-level-3\">4.7.4 \ub300\uccb4\uc7ac\uc758 \uc704\ud611<\/li>\n<li class=\"toc-level-3\">4.7.5 \uacbd\uc7c1 \uac15\ub3c4<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-4\">5. \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc131\uc7a5 \uc608\uce21 (\uac00\uce58, USD)<\/p>\n<ul>\n<li class=\"toc-level-2\">5.1 \uce58\ub8cc \uc720\ud615\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.1.1 \uc720\uc804\uc790 \uce58\ub8cc<\/li>\n<li class=\"toc-level-3\">5.1.2 \uc138\ud3ec \uce58\ub8cc<\/li>\n<li class=\"toc-level-3\">5.1.3 \uc870\uc9c1 \uacf5\ud559 \uc81c\ud488<\/li>\n<li class=\"toc-level-3\">5.1.4 \ubcf5\ud569 ATMP<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.2 \uc11c\ube44\uc2a4 \uc720\ud615\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.2.1 \uacf5\uc815 \uac1c\ubc1c<\/li>\n<li class=\"toc-level-3\">5.2.2 CGMP \uc81c\uc870<\/li>\n<li class=\"toc-level-3\">5.2.3 \ucda9\uc804-\uc644\uc131 &amp; \ud3ec\uc7a5<\/li>\n<li class=\"toc-level-3\">5.2.4 \ubd84\uc11d &amp; QC \ud14c\uc2a4\ud2b8<\/li>\n<li class=\"toc-level-3\">5.2.5 \uaddc\uc81c &amp; QA \uc9c0\uc6d0<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.3 \uac1c\ubc1c \ub2e8\uacc4\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.3.1 \uc804\uc784\uc0c1<\/li>\n<li class=\"toc-level-3\">5.3.2 1\uc0c1<\/li>\n<li class=\"toc-level-3\">5.3.3 2\uc0c1<\/li>\n<li class=\"toc-level-3\">5.3.4 3\uc0c1<\/li>\n<li class=\"toc-level-3\">5.3.5 \uc0c1\uc5c5\ud654<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.4 \ubca1\ud130 \uc720\ud615\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.4.1 \uc544\ub370\ub178 \uad00\ub828 \ubc14\uc774\ub7ec\uc2a4 (AAV)<\/li>\n<li class=\"toc-level-3\">5.4.2 \ub80c\ud2f0\ubc14\uc774\ub7ec\uc2a4<\/li>\n<li class=\"toc-level-3\">5.4.3 \ub808\ud2b8\ub85c\ubc14\uc774\ub7ec\uc2a4 &amp; \uac10\ub9c8-\ub808\ud2b8\ub85c\ubc14\uc774\ub7ec\uc2a4<\/li>\n<li class=\"toc-level-3\">5.4.4 \ube44\ubc14\uc774\ub7ec\uc2a4\uc131 \/ \ud50c\ub77c\uc2a4\ubbf8\ub4dc<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.5 \uc138\ud3ec \uacf5\uae09\uc6d0\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.5.1 \uc790\uac00\uc720\ub798<\/li>\n<li class=\"toc-level-3\">5.5.2 \ub3d9\uc885\uc720\ub798<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.6 \uc9c0\uc5ed\ubcc4\n<ul>\n<li class=\"toc-level-3\">5.6.1 \ubd81\ubbf8\n<ul>\n<li class=\"toc-level-4\">5.6.1.1 \ubbf8\uad6d<\/li>\n<li class=\"toc-level-4\">5.6.1.2 \uce90\ub098\ub2e4<\/li>\n<li class=\"toc-level-4\">5.6.1.3 \uba55\uc2dc\ucf54<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-3\">5.6.2 \uc720\ub7fd\n<ul>\n<li class=\"toc-level-4\">5.6.2.1 \ub3c5\uc77c<\/li>\n<li class=\"toc-level-4\">5.6.2.2 \uc601\uad6d<\/li>\n<li class=\"toc-level-4\">5.6.2.3 \ud504\ub791\uc2a4<\/li>\n<li class=\"toc-level-4\">5.6.2.4 \uc774\ud0c8\ub9ac\uc544<\/li>\n<li class=\"toc-level-4\">5.6.2.5 \uc2a4\ud398\uc778<\/li>\n<li class=\"toc-level-4\">5.6.2.6 \uc720\ub7fd \uae30\ud0c0 \uc9c0\uc5ed<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-3\">5.6.3 \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591\n<ul>\n<li class=\"toc-level-4\">5.6.3.1 \uc911\uad6d<\/li>\n<li class=\"toc-level-4\">5.6.3.2 \uc77c\ubcf8<\/li>\n<li class=\"toc-level-4\">5.6.3.3 \uc778\ub3c4<\/li>\n<li class=\"toc-level-4\">5.6.3.4 \ud638\uc8fc<\/li>\n<li class=\"toc-level-4\">5.6.3.5 \ub300\ud55c\ubbfc\uad6d<\/li>\n<li class=\"toc-level-4\">5.6.3.6 \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591 \uae30\ud0c0 \uc9c0\uc5ed<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-3\">5.6.4 \uc911\ub3d9 &amp; \uc544\ud504\ub9ac\uce74\n<ul>\n<li class=\"toc-level-4\">5.6.4.1 GCC<\/li>\n<li class=\"toc-level-4\">5.6.4.2 \ub0a8\uc544\ud504\ub9ac\uce74<\/li>\n<li class=\"toc-level-4\">5.6.4.3 \uc911\ub3d9 &amp; \uc544\ud504\ub9ac\uce74 \uae30\ud0c0 \uc9c0\uc5ed<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-3\">5.6.5 \ub0a8\ubbf8\n<ul>\n<li class=\"toc-level-4\">5.6.5.1 \ube0c\ub77c\uc9c8<\/li>\n<li class=\"toc-level-4\">5.6.5.2 \uc544\ub974\ud5e8\ud2f0\ub098<\/li>\n<li class=\"toc-level-4\">5.6.5.3 \ub0a8\ubbf8 \uae30\ud0c0 \uc9c0\uc5ed<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-5\">6. \uacbd\uc7c1 \ud658\uacbd<\/p>\n<ul>\n<li class=\"toc-level-2\">6.1 \uc2dc\uc7a5 \uc9d1\uc911\ub3c4<\/li>\n<li class=\"toc-level-2\">6.2 \uc2dc\uc7a5 \uc810\uc720\uc728 \ubd84\uc11d<\/li>\n<li class=\"toc-level-2\">6.3 \uae30\uc5c5 \ud504\ub85c\ud544 {(\uae00\ub85c\ubc8c \uac1c\uc694, \uc2dc\uc7a5 \uac1c\uc694, \ud575\uc2ec \ubd80\ubb38, \uc7ac\ubb34 \uc815\ubcf4(\uc0ac\uc6a9 \uac00\ub2a5\ud55c \uacbd\uc6b0), \uc804\ub7b5 \uc815\ubcf4, \uc8fc\uc694 \uae30\uc5c5 \uc2dc\uc7a5 \uc21c\uc704\/\uc810\uc720\uc728, \uc81c\ud488 \ubc0f \uc11c\ube44\uc2a4, \ucd5c\uc2e0 \uac1c\ubc1c \ud3ec\ud568)}\n<ul>\n<li class=\"toc-level-3\">6.3.1 3P Biopharmaceuticals S.L.U.<\/li>\n<li class=\"toc-level-3\">6.3.2 AGC Biologics (AGC Inc.)<\/li>\n<li class=\"toc-level-3\">6.3.3 Batavia Biosciences B.V.<\/li>\n<li class=\"toc-level-3\">6.3.4 BioNTech SE (\uacc4\uc57d \uc11c\ube44\uc2a4)<\/li>\n<li class=\"toc-level-3\">6.3.5 Catalent Inc.<\/li>\n<li class=\"toc-level-3\">6.3.6 Centre For Breakthrough Medicines LLC<\/li>\n<li class=\"toc-level-3\">6.3.7 CGT Catapult (\uc138\ud3ec \ubc0f \uc720\uc804\uc790 \uce58\ub8cc \uce74\ud0c0\ud384\ud2b8)<\/li>\n<li class=\"toc-level-3\">6.3.8 Charles River Laboratories International Inc.<\/li>\n<li class=\"toc-level-3\">6.3.9 Celltrion Inc.<\/li>\n<li class=\"toc-level-3\">6.3.10 Fujifilm Diosynth Biotechnologies<\/li>\n<li class=\"toc-level-3\">6.3.11 Lonza Group Ltd.<\/li>\n<li class=\"toc-level-3\">6.3.12 Luina Bio Pty Ltd.<\/li>\n<li class=\"toc-level-3\">6.3.13 Minaris Regenerative Medicine GmbH<\/li>\n<li class=\"toc-level-3\">6.3.14 Oxford Biomedica Plc<\/li>\n<li class=\"toc-level-3\">6.3.15 Resilience (National Resilience Inc.)<\/li>\n<li class=\"toc-level-3\">6.3.16 RoslinCT Ltd.<\/li>\n<li class=\"toc-level-3\">6.3.17 Samsung Biologics Co., Ltd.<\/li>\n<li class=\"toc-level-3\">6.3.18 Thermo Fisher Scientific Inc.<\/li>\n<li class=\"toc-level-3\">6.3.19 Vibalogics GmbH (Recipharm AB)<\/li>\n<li class=\"toc-level-3\">6.3.20 Viralgen Vector Core (AskBio\/Bayer AG)<\/li>\n<li class=\"toc-level-3\">6.3.21 WuXi AppTec Co., Ltd. (WuXi Advanced Therapies)<\/li>\n<li class=\"toc-level-3\">6.3.22 Yposkesi (Erytech Pharma SA)<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-6\">7. \uc2dc\uc7a5 \uae30\ud68c &amp; \ubbf8\ub798 \uc804\ub9dd<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Advanced Therapy Medicinal Products (ATMP) CDMO \uc2dc\uc7a5 \uac1c\uc694<\/p>\n<p>Advanced Therapy Medicinal Products (ATMP) CDMO \uc2dc\uc7a5\uc740 2025\ub144 75.1\uc5b5 \ub2ec\ub7ec\uc5d0\uc11c 2026\ub144 93.4\uc5b5 \ub2ec\ub7ec\ub85c \uc131\uc7a5\ud588\uc73c\uba70, 2031\ub144\uc5d0\ub294 278.3\uc5b5 \ub2ec\ub7ec\uc5d0 \ub2ec\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. \uc774\ub294 2026\ub144\ubd80\ud130 2031\ub144\uae4c\uc9c0 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960(CAGR) 24.40%\ub97c \uae30\ub85d\ud560 \uc804\ub9dd\uc785\ub2c8\ub2e4. \uc774\ub7ec\ud55c \uc131\uc7a5\uc740 \ubbf8\uad6d \uc2dd\ud488\uc758\uc57d\uad6d(FDA) \ubc0f \uc720\ub7fd\uc758\uc57d\ud488\uccad(EMA)\uc758 \uc2e0\uaddc \uc2b9\uc778 \uc99d\uac00, \uc784\uc0c1 \uac1c\ubc1c \uae30\uac04 \ub2e8\ucd95, \uc790\uac00(autologous) \ubc0f \ub3d9\uc885(allogeneic) \uc81c\uc870 \ud50c\ub7ab\ud3fc\uc758 \ubcf5\uc7a1\uc131 \uc99d\ub300\uc5d0\uc11c \ube44\ub86f\ub429\ub2c8\ub2e4. \uc2a4\ud3f0\uc11c\ub4e4\uc740 \uac1c\ubc1c \ucd08\uae30 \ub2e8\uacc4\ubd80\ud130 \ub2e4\ub144\uac04\uc758 \uacc4\uc57d\uc744 \uccb4\uacb0\ud558\uba70, CDMO(\uc704\ud0c1\uac1c\ubc1c\uc0dd\uc0b0\uae30\uad00)\ub294 \uacf5\uc815 \ub178\ud558\uc6b0, \uaddc\uc81c \uc9c0\uce68, \uc790\ubcf8 \uc9d1\uc57d\uc801 \uc0dd\uc0b0 \uc5ed\ub7c9\uc744 \uc81c\uacf5\ud558\ub294 \uc804\ub7b5\uc801 \ud30c\ud2b8\ub108\ub85c \ubcc0\ubaa8\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ud2b9\ud788 \ubc14\uc774\ub7ec\uc2a4 \ubca1\ud130 \ud504\ub85c\uc81d\ud2b8\uc5d0 \ub300\ud55c \uc790\ubcf8 \uc9c0\ucd9c\uc774 \uc9c0\ubc30\uc801\uc774\uba70, \ud3d0\uc1c4\ud615 \uc790\ub3d9\ud654 \uc138\ud3ec \ucc98\ub9ac \uc2dc\uc2a4\ud15c\uc758 \ube60\ub978 \ub3c4\uc785\uc740 \uc0dd\uc0b0 \ub9ac\ub4dc \ud0c0\uc784\uc744 \ub2e8\ucd95\ud558\uace0 \uc624\uc5fc \uc704\ud5d8\uc744 \ub0ae\ucd94\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ub610\ud55c, \ub514\uc9c0\ud138 \ud2b8\uc708 \uc18c\ud504\ud2b8\uc6e8\uc5b4\ub294 \ud575\uc2ec \uacf5\uc815 \ub9e4\uac1c\ubcc0\uc218 \ubaa8\ub378\ub9c1\uc744 \uac00\ub2a5\ud558\uac8c \ud558\uc5ec \uc5d4\uc9c0\ub2c8\uc5b4\ub9c1 \uc2e4\ud589\uc744 \uc808\ubc18\uc73c\ub85c \uc904\uc774\uace0 FDA \uc0dd\ubb3c\ud559\uc801 \uc81c\uc81c \ud3c9\uac00 \uc5f0\uad6c\uc13c\ud130(CBER)\uc758 \uc2e4\uc2dc\uac04 \ucd9c\uc2dc \uae30\ub300\uce58\ub97c \ucda9\uc871\uc2dc\ud0a4\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uc8fc\uc694 \ubcf4\uace0\uc11c \uc694\uc57d<\/p>\n<p>*   \uce58\ub8cc \uc720\ud615\ubcc4: \uc138\ud3ec \uce58\ub8cc\uac00 2025\ub144 \ub9e4\ucd9c\uc758 60.21%\ub97c \ucc28\uc9c0\ud588\uc73c\uba70, \uc720\uc804\uc790 \uce58\ub8cc\ub294 2031\ub144\uae4c\uc9c0 26.43%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.<br \/>\n*   \uc11c\ube44\uc2a4 \uc720\ud615\ubcc4: cGMP(\uc6b0\uc218 \uc758\uc57d\ud488 \uc81c\uc870 \ubc0f \ud488\uc9c8 \uad00\ub9ac \uae30\uc900) \uc81c\uc870\uac00 2025\ub144 \ub9e4\ucd9c\uc758 45.78%\ub97c \uae30\uc5ec\ud588\uc73c\uba70, \uaddc\uc81c \ubc0f \ud488\uc9c8 \ubcf4\uc99d \uc9c0\uc6d0\uc740 2031\ub144\uae4c\uc9c0 26.87%\uc758 CAGR\ub85c \uc131\uc7a5\ud560 \uc804\ub9dd\uc785\ub2c8\ub2e4.<br \/>\n*   \uac1c\ubc1c \ub2e8\uacc4\ubcc4: 3\uc0c1 \uc784\uc0c1\uc2dc\ud5d8\uc774 2025\ub144 \uc218\uc694\uc758 43.83%\ub97c \ucc28\uc9c0\ud588\uc73c\ub098, \uc804\uc784\uc0c1 \uc5f0\uad6c\ub294 \uc608\uce21 \uae30\uac04 \ub3d9\uc548 27.11%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \ubcf4\uc785\ub2c8\ub2e4.<br \/>\n*   \ubca1\ud130 \uc720\ud615\ubcc4: \uc544\ub370\ub178 \uad00\ub828 \ubc14\uc774\ub7ec\uc2a4(AAV)\uac00 2025\ub144 36.76%\ub97c \uc810\uc720\ud588\uc73c\uba70, \ub80c\ud2f0\ubc14\uc774\ub7ec\uc2a4 \ubca1\ud130\ub294 2031\ub144\uae4c\uc9c0 26.66%\ub85c \ud655\uc7a5\ub420 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.<br \/>\n*   \uc138\ud3ec \uacf5\uae09\uc6d0\ubcc4: \uc790\uac00(Autologous) \ubc29\uc2dd\uc774 2025\ub144 55.76%\ub85c \uc120\ub450\ub97c \ub2ec\ub838\uc73c\uba70, \ub3d9\uc885(Allogeneic) \uc811\uadfc \ubc29\uc2dd\uc740 2031\ub144\uae4c\uc9c0 27.43%\ub85c \uc131\uc7a5\ud560 \uac83\uc785\ub2c8\ub2e4.<br \/>\n*   \uc9c0\uc5ed\ubcc4: \ubd81\ubbf8\uac00 2025\ub144 \ub9e4\ucd9c\uc758 42.76%\ub97c \ucc28\uc9c0\ud558\uba70 \uac00\uc7a5 \ud070 \uc2dc\uc7a5\uc774\uc5c8\uace0, \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591 \uc9c0\uc5ed\uc740 2031\ub144\uae4c\uc9c0 25.76%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4.<br \/>\n*   \uc2dc\uc7a5 \uc9d1\uc911\ub3c4: \uc911\uac04 \uc218\uc900\uc785\ub2c8\ub2e4.<\/p>\n<p>\uae00\ub85c\ubc8c ATMP CDMO \uc2dc\uc7a5 \ub3d9\ud5a5 \ubc0f \ud1b5\ucc30\ub825<\/p>\n<p>\uc131\uc7a5 \ub3d9\ub825:<\/p>\n<p>1.  \uc2b9\uc778\ub41c \uc138\ud3ec \ubc0f \uc720\uc804\uc790 \uce58\ub8cc\uc81c\uc758 \uae09\uc18d\ud55c \ud655\uc7a5: 2024-2025\ub144 FDA\uc640 EMA\ub294 27\uac1c\uc758 \ucca8\ub2e8 \uce58\ub8cc\uc81c\ub97c \uc2b9\uc778\ud558\uc5ec \ucd08\ud76c\uadc0 \uc9c8\ud658\ubd80\ud130 \uc720\ubcd1\ub960\uc774 \ub192\uc740 \uc9c8\ud658\uae4c\uc9c0 \uc801\uc751\uc99d\uc744 \ud655\ub300\ud588\uc2b5\ub2c8\ub2e4. \uac01 \uc2b9\uc778\uc740 \uac1c\ubcc4\uc801\uc778 \uc81c\uc870 \uc2dc\uc124\uc744 \uc694\uad6c\ud558\uba70, CDMO\ub294 \ubcd1\ub82c \ubca1\ud130 \ubc0f \uc138\ud3ec \ud50c\ub7ab\ud3fc\uc744 \uc6b4\uc601\ud574\uc57c \ud569\ub2c8\ub2e4. EMA\uc758 PRIME \uacbd\ub85c\ub294 \uac1c\ubc1c \uae30\uac04\uc744 \uc57d 18\uac1c\uc6d4 \ub2e8\ucd95\uc2dc\ucf1c \uc2a4\ud3f0\uc11c\ub4e4\uc774 1\uc0c1 \uc784\uc0c1\uc2dc\ud5d8 \uc911 \uc0c1\uc5c5\uc801 \uc0dd\uc0b0 \uc2ac\ub86f\uc744 \uc608\uc57d\ud558\uac8c \ub9cc\ub4e4\uc5c8\uc2b5\ub2c8\ub2e4.<br \/>\n2.  \uc911\uc18c\ud615 \ubc14\uc774\uc624\ud14d \uc2a4\ud3f0\uc11c\uc758 \uc544\uc6c3\uc18c\uc2f1 \ucd94\uc138: \uc790\uae08\ub825\uc774 \ubd80\uc871\ud55c \ubc14\uc774\uc624\ud14d \uae30\uc5c5\ub4e4\uc740 \ub0b4\ubd80 \uc0dd\uc0b0 \uc2dc\uc124\uc744 \uc790\ubcf8 \ud568\uc815\uc73c\ub85c \uc778\uc2dd\ud558\uba70, \ucd08\uae30 \ub2e8\uacc4 \uac1c\ubc1c\uc0ac\uc758 \uc57d 90%\uac00 \ucd5c\uc18c \ud558\ub098\uc758 cGMP \uc791\uc5c5\uc744 \uc544\uc6c3\uc18c\uc2f1\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc774\ub294 2023\ub144 \ub300\ube44 30%\ud3ec\uc778\ud2b8 \uc99d\uac00\ud55c \uc218\uce58\uc785\ub2c8\ub2e4. CDMO\uac00 \ubbf8\ub798 \ubb3c\ub7c9 \ud655\ubcf4\ub97c \uc704\ud574 \uacf5\uc815 \uac1c\ubc1c\uc5d0 \uacf5\ub3d9 \ud22c\uc790\ud558\ub294 \uc704\ud5d8 \uacf5\uc720 \uacc4\uc57d\uc774 \uc77c\ubc18\ud654\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n3.  \ubc14\uc774\ub7ec\uc2a4 \ubca1\ud130 \uc81c\uc870 \uc5ed\ub7c9\uc5d0 \ub300\ud55c \ud22c\uc790 \ud655\ub300: \ud6c4\uc9c0\ud544\ub984\uc740 2024\ub144 \ub178\uc2a4\uce90\ub864\ub77c\uc774\ub098 \uc720\uc804\uc790 \uce58\ub8cc \ucea0\ud37c\uc2a4 \ud655\uc7a5\uc5d0 12\uc5b5 \ub2ec\ub7ec\ub97c \ud22c\uc790\ud558\uc5ec 20\ub9cc \ub9ac\ud130\uc758 \ubd80\uc720 \ubc30\uc591 \ubc14\uc774\uc624\ub9ac\uc561\ud130 \uc6a9\ub7c9\uc744 \ucd94\uac00\ud588\uc2b5\ub2c8\ub2e4. AGC \ubc14\uc774\uc624\ub85c\uc9c1\uc2a4\ub294 2025\ub144 \uc544\uc2dc\uc544 \uc218\uc694 \uc99d\uac00\uc5d0 \ub300\uc751\ud558\uc5ec \uc694\ucf54\ud558\ub9c8\uc5d0 \ub80c\ud2f0\ubc14\uc774\ub7ec\uc2a4 \uc2dc\uc124\uc5d0 3\uc5b5 5\ucc9c\ub9cc \ub2ec\ub7ec\ub97c \ud560\ub2f9\ud588\uc2b5\ub2c8\ub2e4.<br \/>\n4.  \ud3d0\uc1c4\ud615 \ubaa8\ub4c8\uc2dd \uc81c\uc870 \uc2dc\uc2a4\ud15c \ub3c4\uc785: Cellares\uc758 \uc644\uc804 \uc790\ub3d9\ud654\ub41c Cell Shuttle\uc740 7\uc77c \ub9cc\uc5d0 \uc784\uc0c1 \ub4f1\uae09 CAR-T \uc0dd\uc0b0\uc744 \uc2dc\uc5f0\ud558\uc5ec 2024\ub144 Bristol Myers Squibb\uc640 3\uc5b5 8\ucc9c\ub9cc \ub2ec\ub7ec \uaddc\ubaa8\uc758 \ud30c\ud2b8\ub108\uc2ed\uc744 \uc774\ub04c\uc5b4\ub0c8\uc2b5\ub2c8\ub2e4. Lonza\uc758 Cocoon \ubc0f Miltenyi\uc758 CliniMACS Prodigy\ub3c4 \uac1c\ubc29\ud615 \ucde8\uae09\uc744 \uc5c6\uc560 \uc804 \uc138\uacc4 \uae30\uc220 \uc774\uc804\uc744 \uc6a9\uc774\ud558\uac8c \ud558\uace0 \uc624\uc5fc\uc744 \uc904\uc785\ub2c8\ub2e4.<br \/>\n5.  \ubc14\uc774\uc624 \uacf5\uc815 \ucd5c\uc801\ud654\ub97c \uc704\ud55c \ub514\uc9c0\ud138 \ud2b8\uc708 \ud50c\ub7ab\ud3fc: \ub514\uc9c0\ud138 \ud2b8\uc708 \uc18c\ud504\ud2b8\uc6e8\uc5b4\ub294 \uc5d4\uc9c0\ub2c8\uc5b4\ub4e4\uc774 \ud575\uc2ec \uacf5\uc815 \ub9e4\uac1c\ubcc0\uc218\ub97c \ubaa8\ub378\ub9c1\ud558\uc5ec \uc5d4\uc9c0\ub2c8\uc5b4\ub9c1 \uc2e4\ud589\uc744 \uc808\ubc18\uc73c\ub85c \uc904\uc774\uace0 FDA\uc758 \uc2e4\uc2dc\uac04 \ucd9c\uc2dc \uae30\ub300\uce58\ub97c \ucda9\uc871\uc2dc\ud0a4\ub294 \ub370 \uae30\uc5ec\ud569\ub2c8\ub2e4.<br \/>\n6.  &#8220;Vein-to-Vein&#8221; \uc2dc\uac04 \ub2e8\ucd95\uc744 \uc704\ud55c \uacf5\uae09\ub9dd \uc9c0\uc5ed\ud654: \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591 \uc9c0\uc5ed\uc744 \uc911\uc2ec\uc73c\ub85c \uacf5\uae09\ub9dd \uc9c0\uc5ed\ud654\uac00 \uc9c4\ud589\ub418\uace0 \uc788\uc73c\uba70, \uc774\ub294 \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74, \ub0a8\ubbf8 \uc9c0\uc5ed\uc73c\ub85c \ud655\uc0b0\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uc81c\uc57d \uc694\uc778:<\/p>\n<p>1.  \uc219\ub828\ub41c \ucca8\ub2e8 \uce58\ub8cc\uc81c \uc778\ub825\uc758 \ub9cc\uc131\uc801\uc778 \ubd80\uc871: \uc7ac\uc0dd\uc758\ud559\uc5f0\ud569(Alliance for Regenerative Medicine)\uc740 2028\ub144\uae4c\uc9c0 \uc81c\uc870, \ud488\uc9c8 \uad00\ub9ac, \uaddc\uc81c \ubd84\uc57c\uc5d0\uc11c \uc804 \uc138\uacc4\uc801\uc73c\ub85c 2\ub9cc \uba85\uc758 \uc778\ub825 \ubd80\uc871\uc744 \uc608\uc0c1\ud569\ub2c8\ub2e4. CDMO\ub4e4\uc740 \uc0c8\ub85c\uc6b4 AAV \ud300\uc758 \uc628\ubcf4\ub529 \ub9ac\ub4dc \ud0c0\uc784\uc774 2022\ub144\uc5d0\uc11c 2025\ub144 \uc0ac\uc774\uc5d0 6\uac1c\uc6d4\uc5d0\uc11c 12\uac1c\uc6d4\ub85c \ub298\uc5b4\ub0ac\ub2e4\uace0 \ubcf4\uace0\ud569\ub2c8\ub2e4.<br \/>\n2.  cGMP \uc900\uc218 \uc2dc\uc124\uc5d0 \ub300\ud55c \ub192\uc740 \uc790\ubcf8 \uc9c0\ucd9c: 500\ub9ac\ud130 \uaddc\ubaa8\uc758 \ubc14\uc774\ub7ec\uc2a4 \ubca1\ud130 \uc2dc\uc124\uc744 \uac74\uc124\ud558\ub294 \ub370\ub294 \uc911\ubcf5 \uc720\ud2f8\ub9ac\ud2f0 \ubc0f ISO 7 \ud074\ub9b0\ub8f8\uc744 \ud3ec\ud568\ud558\uc5ec 1\uc5b5 5\ucc9c\ub9cc \ub2ec\ub7ec \uc774\uc0c1\uc774 \uc18c\uc694\ub418\uc5b4 \uc911\uacac \uae30\uc5c5\uc758 \uc9c4\uc785\uc744 \uc5b4\ub835\uac8c \ud569\ub2c8\ub2e4.<br \/>\n3.  cGMP \ub4f1\uae09 \ud50c\ub77c\uc2a4\ubbf8\ub4dc \uc6d0\ub8cc\uc758 \uc81c\ud55c\ub41c \uacf5\uae09: \ubd81\ubbf8\uc640 \uc720\ub7fd\uc5d0\uc11c \ubcd1\ubaa9 \ud604\uc0c1\uc774 \ubc1c\uc0dd\ud558\uba70 \uc804 \uc138\uacc4\uc801\uc73c\ub85c \uacf5\uae09\uc774 \uc81c\ud55c\uc801\uc785\ub2c8\ub2e4.<br \/>\n4.  \uad6d\uacbd \uac04 \ubca1\ud130 \uacf5\uae09\uc5d0 \ub300\ud55c \uc9c0\uc815\ud559\uc801 \uac10\uc2dc \uac15\ud654: \ubd81\ubbf8, \uc720\ub7fd, \uc911\uad6d \ub4f1 \uc8fc\uc694 \uc9c0\uc5ed\uc5d0\uc11c \uad6d\uacbd \uac04 \ubca1\ud130 \uacf5\uae09\uc5d0 \ub300\ud55c \uc9c0\uc815\ud559\uc801 \uac10\uc2dc\uac00 \uac15\ud654\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uc138\uadf8\uba3c\ud2b8 \ubd84\uc11d<\/p>\n<p>*   \uce58\ub8cc \uc720\ud615\ubcc4: \uc138\ud3ec \uce58\ub8cc\ub294 \uc0c1\uc5c5\uc6a9 CAR-T \ud504\ub85c\uadf8\ub7a8\uc5d0 \ud798\uc785\uc5b4 2025\ub144 ATMP CDMO \uc2dc\uc7a5 \uc810\uc720\uc728\uc758 60.21%\ub97c \ucc28\uc9c0\ud588\uc2b5\ub2c8\ub2e4. \uc720\uc804\uc790 \uce58\ub8cc\ub294 \ud608\uc6b0\ubcd1 \ubc0f \ub4a4\uc13c \uadfc\uc774\uc601\uc591\uc99d\uc744 \uc704\ud55c \uc0dd\uccb4 \ub0b4 AAV \ud50c\ub7ab\ud3fc\uc5d0 \uc758\ud574 2031\ub144\uae4c\uc9c0 26.43%\uc758 CAGR\ub85c \uc131\uc7a5\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc138\ud3ec \uce58\ub8cc\ub294 \ud658\uc790 \ub9de\ucda4\ud615 \ubc30\uce58\ub85c \uc778\ud574 \ub192\uc740 \uac00\uaca9\uc744 \ud615\uc131\ud558\ub294 \ubc18\uba74, \uc720\uc804\uc790 \uce58\ub8cc\ub294 \ub300\uaddc\ubaa8 \ud658\uc790 \ucf54\ud638\ud2b8\uc5d0 \uace0\uc815 \ube44\uc6a9\uc744 \ubd84\uc0b0\uc2dc\ud0a4\ub294 \ud480\ub9c1 \uc81c\uc870 \ubc29\uc2dd\uc73c\ub85c \ub9c8\uc9c4 \ud655\uc7a5\uc131\uc774 \ub6f0\uc5b4\ub0a9\ub2c8\ub2e4.<br \/>\n*   \uc11c\ube44\uc2a4 \uc720\ud615\ubcc4: cGMP \uc81c\uc870\ub294 \ubc14\uc774\ub7ec\uc2a4 \ubca1\ud130 \uc0dd\uc0b0 \ubc0f \ubcf5\uc7a1\ud55c \uc138\ud3ec \ucc98\ub9ac \uc6cc\ud06c\ud50c\ub85c\uc6b0\uc640 \uad00\ub828\ub41c \ub192\uc740 \ubc30\uce58\ub2f9 \uc218\uc218\ub8cc\ub85c \uc778\ud574 2025\ub144 \ub9e4\ucd9c\uc758 45.78%\ub97c \ucc28\uc9c0\ud588\uc2b5\ub2c8\ub2e4. \uaddc\uc81c \ubc0f \ud488\uc9c8 \uc9c0\uc6d0\uc740 FDA, EMA, NMPA(\uad6d\uac00\uc57d\ud488\uac10\ub3c5\uad00\ub9ac\uad6d)\uc758 \uc0c1\uc774\ud55c \uc11c\ub958 \uc81c\ucd9c \uc694\uad6c\uc0ac\ud56d\uc744 \ubc18\uc601\ud558\uc5ec 26.87%\uc758 CAGR\ub85c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.<br \/>\n*   \uac1c\ubc1c \ub2e8\uacc4\ubcc4: 2022-2024\ub144 \uc0ac\uc774\uc5d0 \uc218\ub9ce\uc740 \ud575\uc2ec \uc784\uc0c1\uc2dc\ud5d8\uc774 \uc2dc\uc791\ub418\uba74\uc11c 3\uc0c1 \ud504\ub85c\uadf8\ub7a8\uc774 2025\ub144 \uc9c0\ucd9c\uc758 43.83%\ub97c \ucc28\uc9c0\ud588\uc2b5\ub2c8\ub2e4. \uc804\uc784\uc0c1 \ub2e8\uacc4\ub294 \ubca4\ucc98 \ud22c\uc790 \ubc14\uc774\uc624\ud14d \uae30\uc5c5\ub4e4\uc774 \ub0b4\ubd80 \uc2dc\uc124 \uad6c\ucd95 \uc804\uc5d0 CDMO\ub97c \ud65c\uc6a9\ud558\uc5ec CMC(\ud654\ud559, \uc81c\uc870 \ubc0f \uad00\ub9ac) \uc704\ud5d8\uc744 \uc904\uc774\ub294 \ub370 \ud798\uc785\uc5b4 27.11%\uc758 CAGR\ub85c \uc131\uc7a5\ud560 \uc608\uc815\uc785\ub2c8\ub2e4.<br \/>\n*   \ubca1\ud130 \uc720\ud615\ubcc4: AAV\ub294 \uc0dd\uccb4 \ub0b4 \uc720\uc804\uc790 \uc804\ub2ec \ubd84\uc57c\uc5d0\uc11c \uc120\ub450\ub97c \uc720\uc9c0\ud558\uba70 2025\ub144 \ub9e4\ucd9c\uc758 36.76%\ub97c \ucc28\uc9c0\ud588\uc2b5\ub2c8\ub2e4. \ub80c\ud2f0\ubc14\uc774\ub7ec\uc2a4 \ubca1\ud130\ub294 \ub3d9\uc885 CAR-T \ubc0f NK \ud30c\uc774\ud504\ub77c\uc778\uc774 \uc131\uc7a5\ud568\uc5d0 \ub530\ub77c 26.66%\uc758 CAGR \uada4\ub3c4\uc5d0 \uc788\uc2b5\ub2c8\ub2e4. \ub808\ud2b8\ub85c\ubc14\uc774\ub7ec\uc2a4 \uc2dc\uc2a4\ud15c\uc740 \uc904\uae30\uc138\ud3ec \uccb4\uc678 \ud658\uacbd\uc5d0\uc11c \ud2c8\uc0c8 \uc6a9\ub3c4\ub85c \uc0ac\uc6a9\ub418\uba70, \ube44\ubc14\uc774\ub7ec\uc2a4\uc131 \uc9c0\uc9c8 \ub098\ub178\uc785\uc790\ub294 mRNA \uce58\ub8cc\uc81c \ubc0f \uccb4\uc678 \ud3b8\uc9d1\uc5d0 \ud65c\uc6a9\ub429\ub2c8\ub2e4.<br \/>\n*   \uc138\ud3ec \uacf5\uae09\uc6d0\ubcc4: \uc790\uac00(Autologous) \uc81c\ud488\uc740 \uc2b9\uc778\ub41c CAR-T \ube0c\ub79c\ub4dc\uc5d0 \ud798\uc785\uc5b4 2025\ub144 \ub9e4\ucd9c\uc758 55.76%\ub97c \uae30\ub85d\ud588\uc2b5\ub2c8\ub2e4. \ub3d9\uc885(Allogeneic) \ubc29\uc2dd\uc740 \ud658\uc790\ubcc4 \ubc30\uce58 \uae30\ub85d\uc744 \uc5c6\uc560\uace0 \uc6a9\ub7c9\ub2f9 \ube44\uc6a9\uc744 \uc790\uac00 \ubc29\uc2dd\uc758 \uc57d 4\ubd84\uc758 1\ub85c \uc808\uac10\ud558\uc5ec 27.43%\uc758 CAGR\uc744 \ubcf4\uc77c \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.<\/p>\n<p>\uc9c0\uc5ed \ubd84\uc11d<\/p>\n<p>*   \ubd81\ubbf8: \uc870\ubc00\ud55c \uc784\uc0c1 \ud30c\uc774\ud504\ub77c\uc778, FDA \uaddc\uc81c \uba85\ud655\uc131, \ubcf4\uc2a4\ud134-\ucea0\ube0c\ub9ac\uc9c0 \ubc0f \uc0cc\ud504\ub780\uc2dc\uc2a4\ucf54 CDMO \ud074\ub7ec\uc2a4\ud130\uc758 \uadfc\uc811\uc131 \ub355\ubd84\uc5d0 2025\ub144 \ub9e4\ucd9c\uc758 42.76%\ub97c \ucc28\uc9c0\ud588\uc2b5\ub2c8\ub2e4. \uadf8\ub7ec\ub098 \uc5ed\ub7c9 \ubcd1\ubaa9 \ud604\uc0c1\uacfc \uc778\uac74\ube44 \uc0c1\uc2b9\uc740 \uc9c0\uc5ed CAGR\uc744 \uc5b5\uc81c\ud558\uc5ec \uc2a4\ud3f0\uc11c\ub4e4\uc774 \uc720\ub7fd \ubc0f \uc544\uc2dc\uc544 \ub300\uc548\uc744 \ucc3e\ub3c4\ub85d \uc720\ub3c4\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \uc720\ub7fd: 2025\ub144 \ub9e4\ucd9c\uc758 \uc57d 30%\ub97c \ucc28\uc9c0\ud588\uc73c\uba70, \ub3c5\uc77c\uc758 \ubc14\uc774\ub7ec\uc2a4 \ubca1\ud130 \ud5c8\ube0c, \uc601\uad6d\uc758 \uc625\uc2a4\ud3ec\ub4dc-\ucea0\ube0c\ub9ac\uc9c0 \ud68c\ub791, 27\uac1c \uc2dc\uc7a5\uc5d0 \ub300\ud55c \uc811\uadfc\uc744 \ud5c8\uc6a9\ud558\ub294 EMA\uc758 \uc911\uc559 \uc9d1\uc911\uc2dd ATMP \uc2b9\uc778\uc744 \ud65c\uc6a9\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591: \uc911\uad6d\uc758 \uad6d\uac00 \uc138\ud3ec \uce58\ub8cc \ub85c\ub4dc\ub9f5, \uc77c\ubcf8\uc758 \uc870\uac74\ubd80 \uc2b9\uc778 \uc2dc\uc2a4\ud15c, \ud55c\uad6d\uc758 cGMP \ud22c\uc790\uc5d0 \ud798\uc785\uc5b4 2031\ub144\uae4c\uc9c0 25.76%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud560 \uc900\ube44\uac00 \ub418\uc5b4 \uc788\uc2b5\ub2c8\ub2e4. BioNTech\uc758 \uc2f1\uac00\ud3ec\ub974 \uacf5\uc7a5\uacfc WuXi\uc758 \uc464\uc800\uc6b0 \ud655\uc7a5\uc740 &#8220;Vein-to-Vein&#8221; \ubaa9\ud45c \ub2ec\uc131\uc744 \uc704\ud55c \ud604\uc9c0 \uc0dd\uc0b0\uc73c\ub85c\uc758 \uc804\ud658\uc744 \uac15\uc870\ud569\ub2c8\ub2e4.<br \/>\n*   \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74, \ub0a8\ubbf8: 2025\ub144 \uc218\uc694\uc758 5% \ubbf8\ub9cc, 3% \ubbf8\ub9cc\uc744 \ucc28\uc9c0\ud588\uc73c\ub098, \ub450\ubc14\uc774\uc758 2025\ub144 \uc138\ud3ec \uce58\ub8cc \ud5c8\ube0c \ubc0f \uc544\ub974\ud5e8\ud2f0\ub098\uc758 \uac04\uc18c\ud654\ub41c ATMP \uaddc\uc81c\ub294 \ucd08\uae30 \uc131\uc7a5\uc744 \uc2dc\uc0ac\ud569\ub2c8\ub2e4.<\/p>\n<p>\uacbd\uc7c1 \ud658\uacbd<\/p>\n<p>Lonza, Catalent (Novo Holdings), Thermo Fisher Scientific, Samsung Biologics, WuXi Advanced Therapies \ub4f1 5\uac1c \uc120\ub450 \uae30\uc5c5\uc774 \uc124\uce58\ub41c \uc0dd\uc0b0 \uc5ed\ub7c9\uc758 \uc57d 35-40%\ub97c \ud1b5\uc81c\ud558\uba70, ATMP CDMO \uc2dc\uc7a5\uc740 \uc911\uac04 \uc815\ub3c4\uc758 \uc9d1\uc911\ub3c4\ub97c \ubcf4\uc785\ub2c8\ub2e4. 2024\ub144 2\uc6d4 Novo Holdings\uc758 Catalent 165\uc5b5 \ub2ec\ub7ec \uc778\uc218\ub294 \uc218\uc9c1 \ud1b5\ud569\uc758 \uc88b\uc740 \uc608\uc2dc\ub85c, Novo Nordisk\uc5d0 \ubc14\uc774\ub7ec\uc2a4 \ubca1\ud130 \ubc0f \uc138\ud3ec \uc2dc\uc124\uc5d0 \ub300\ud55c \uc6b0\uc120 \uc811\uadfc\uad8c\uc744 \ubd80\uc5ec\ud588\uc2b5\ub2c8\ub2e4. \uc18c\uaddc\ubaa8 \uae30\uc5c5\ub4e4\uc740 \ub80c\ud2f0\ubc14\uc774\ub7ec\uc2a4 \ubd84\uc57c\uc758 Oxford Biomedica, \ud2b9\uc815 AAV \ud608\uccad\ud615 \ubd84\uc57c\uc758 Vibalogics, \ubaa8\ub4c8\uc2dd \ucea0\ud37c\uc2a4 \ubd84\uc57c\uc758 Resilience\uc640 \uac19\uc774 \uc804\ubb38\ud654\ub97c \ud1b5\ud574 \ucc28\ubcc4\ud654\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc790\ub3d9\ud654 \ubc0f \ub370\uc774\ud130 \ubd84\uc11d\uc774 \uacbd\uc7c1\uc744 \ud615\uc131\ud558\uba70, \ub514\uc9c0\ud138 \ud2b8\uc708 \ubc0f \ud3d0\uc1c4\ud615 \uc2dc\uc2a4\ud15c\uc744 \ucc44\ud0dd\ud558\ub294 CDMO\ub294 \uae30\uc220 \uc774\uc804 \uae30\uac04 \ub2e8\ucd95\uc744 \ud1b5\ud574 \ud504\ub9ac\ubbf8\uc5c4 \uac00\uaca9\uc744 \ucc45\uc815\ud569\ub2c8\ub2e4. \uaddc\uc81c \uc774\ub825\uc740 \uc5ec\uc804\ud788 \uacc4\uc57d \uc131\uc0ac\uc758 \uc911\uc694\ud55c \uc694\uc18c\ub85c \uc791\uc6a9\ud558\uba70, FDA Form 483 \uad00\ucc30 \uae30\ub85d\uc774 \uc5c6\ub294 \uc2dc\uc124\uc740 \ub354 \ub192\uc740 \uc785\ucc30 \uc804\ud658\uc728\uc744 \ubcf4\uc785\ub2c8\ub2e4. Cellares\uc758 \uc790\ub3d9\ud654\ub41c \uc138\ud3ec \uce58\ub8cc \uc154\ud2c0\uacfc \uac19\uc740 \uc2e0\ud765 \ud601\uc2e0 \uae30\uc5c5\ub4e4\uc740 \uae30\uc874 \uae30\uc5c5\ub4e4\uc744 \ud6a8\uc728\uc131 \ud5a5\uc0c1\uc73c\ub85c \uc774\ub04c\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc0ac\ubaa8 \ud380\ub4dc\uc640 \ub300\ud615 \uc81c\uc57d\uc0ac\ub4e4\uc774 \ubd80\uc871\ud55c cGMP \uc5ed\ub7c9\uc744 \ud655\ubcf4\ud558\ub824 \ud568\uc5d0 \ub530\ub77c \uc2dc\uc7a5 \ud1b5\ud569\uc740 \uac00\uc18d\ud654\ub420 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.<\/p>\n<p>\ucd5c\uadfc \uc0b0\uc5c5 \ub3d9\ud5a5<\/p>\n<p>*   2025\ub144 3\uc6d4: \ucca8\ub2e8 \uce58\ub8cc\uc81c \uc804\ubb38 CDMO\uc778 Porton Advanced\ub294 \uace0\ud615\uc554 \ubc0f \ud608\uc561\uc554\uc744 \uc704\ud55c \uc0c8\ub85c\uc6b4 T\uc138\ud3ec \uce58\ub8cc\uc81c \uac1c\ubc1c\uc5d0 \uc804\ub150\ud558\ub294 \uc784\uc0c1 \ub2e8\uacc4 \ubc14\uc774\uc624\ud14d \uae30\uc5c5\uc778 Eureka Therapeutics, Inc.\uc640 \ud30c\ud2b8\ub108\uc2ed\uc744 \uccb4\uacb0\ud588\uc2b5\ub2c8\ub2e4.<br \/>\n*   2024\ub144 9\uc6d4: ATMP\ub97c \ud3ec\ud568\ud55c \ubc14\uc774\uc624\uc758\uc57d\ud488 \ubd84\uc57c\uc758 \uc120\ub3c4\uc801\uc778 \uae00\ub85c\ubc8c CDMO\uc778 Rentschler Biopharma SE\ub294 \uc601\uad6d \uc2a4\ud2f0\ubc84\ub2c8\uc9c0\uc5d0 \uc704\uce58\ud55c \ucca8\ub2e8 \uce58\ub8cc\uc81c \uc804\uc6a9 \uc2dc\uc124\uc5d0\uc11c \ud655\uc7a5\ub41c \uc11c\ube44\uc2a4 \uc81c\uacf5\uc744 \uc2dc\uc791\ud588\uc2b5\ub2c8\ub2e4. \uc774 \uac1c\uc120\uc744 \ud1b5\ud574 \uae30\uc874\uc758 \uc544\ub370\ub178 \uad00\ub828 \ubc14\uc774\ub7ec\uc2a4(AAV) \ubca1\ud130 \uc11c\ube44\uc2a4\uc5d0 \ub354\ud574 \uc0c8\ub85c\uc6b4 \ub80c\ud2f0\ubc14\uc774\ub7ec\uc2a4 \ubca1\ud130(LVV) \uc81c\uc870 \ud234\ubc15\uc2a4\uac00 \ub3c4\uc785\ub418\uc5c8\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\ubcf8 \ubcf4\uace0\uc11c\ub294 \uc720\uc804\uc790 \uce58\ub8cc, \uccb4\uc138\ud3ec \uce58\ub8cc, \uc870\uc9c1 \uacf5\ud559 \uc81c\ud488\uc744 \uae30\ubc18\uc73c\ub85c \ud558\ub294 \ud601\uc2e0\uc801\uc778 \uc758\uc57d\ud488\uc778 \ucca8\ub2e8 \uce58\ub8cc \uc758\uc57d\ud488(ATMP)\uc758 CDMO(Contract Development and Manufacturing Organization) \uc2dc\uc7a5\uc5d0 \ub300\ud55c \ud3ec\uad04\uc801\uc778 \ubd84\uc11d\uc744 \uc81c\uacf5\ud569\ub2c8\ub2e4. ATMP\ub294 \ud76c\uadc0\ud558\uace0 \ubcf5\uc7a1\ud55c \uc9c8\ubcd1\uc744 \uce58\ub8cc\ud558\uac70\ub098 \uc644\uce58\ud558\uae30 \uc704\ud574 \uace0\uc548\ub418\uc5c8\uc73c\uba70, \uace0\ub3c4\ub85c \uc804\ubb38\ud654\ub41c \uc81c\uc870 \uacf5\uc815 \ubc0f \uaddc\uc81c \uac10\ub3c5\uc744 \ud544\uc694\ub85c \ud569\ub2c8\ub2e4.<\/p>\n<p>\uc2dc\uc7a5 \uc131\uc7a5\uc744 \uacac\uc778\ud558\ub294 \uc8fc\uc694 \uc694\uc778\uc73c\ub85c\ub294 \uc2b9\uc778\ub41c \uc138\ud3ec \ubc0f \uc720\uc804\uc790 \uce58\ub8cc\uc81c\uc758 \uae09\uc18d\ud55c \ud655\ub300, \uc911\uc18c\ud615 \ubc14\uc774\uc624\ud14d \uc2a4\ud3f0\uc11c\ub4e4\uc758 \uc544\uc6c3\uc18c\uc2f1 \ucd94\uc138 \uc2ec\ud654, \ubc14\uc774\ub7ec\uc2a4 \ubca1\ud130 \uc81c\uc870 \uc5ed\ub7c9\uc5d0 \ub300\ud55c \ud22c\uc790 \uc99d\uac00\uac00 \uc788\uc2b5\ub2c8\ub2e4. \ub610\ud55c, \uc624\uc5fc \uc704\ud5d8\uc744 \uc904\uc774\uace0 \uc0dd\uc0b0 \uc2dc\uac04\uc744 \ub2e8\ucd95\ud558\ub294 \ud3d0\uc1c4\ud615 \ubaa8\ub4c8\uc2dd \uc81c\uc870 \uc2a4\uc704\ud2b8\uc758 \ucc44\ud0dd\uacfc \ubc14\uc774\uc624 \uacf5\uc815 \ucd5c\uc801\ud654\ub97c \uc704\ud55c \ub514\uc9c0\ud138 \ud2b8\uc708 \ud50c\ub7ab\ud3fc\uc758 \ud65c\uc6a9\uc774 \ud655\uc0b0\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uacf5\uae09\ub9dd\uc758 \uc9c0\uc5ed\ud654\ub294 &#8216;Vein-to-Vein&#8217; \uc2dc\uac04\uc744 \ub2e8\ucd95\ud558\ub294 \ub370 \uae30\uc5ec\ud558\uba70 \uc2dc\uc7a5 \uc131\uc7a5\uc744 \ucd09\uc9c4\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\ubc18\uba74, \uc2dc\uc7a5 \uc131\uc7a5\uc744 \uc800\ud574\ud558\ub294 \uc694\uc778\uc73c\ub85c\ub294 \uc219\ub828\ub41c \ucca8\ub2e8 \uce58\ub8cc \uc778\ub825\uc758 \ub9cc\uc131\uc801\uc778 \ubd80\uc871, GMP(Good Manufacturing Practice) \uaddc\uaca9 \uc2dc\uc124 \uad6c\ucd95\uc744 \uc704\ud55c \ub192\uc740 \uc790\ubcf8 \uc9c0\ucd9c, GMP \ub4f1\uae09 \ud50c\ub77c\uc2a4\ubbf8\ub4dc \ucd9c\ubc1c \ubb3c\uc9c8\uc758 \uc81c\ud55c\uc801\uc778 \uacf5\uae09\uc774 \uc788\uc2b5\ub2c8\ub2e4. \uad6d\uacbd\uc744 \ub118\ub294 \ubca1\ud130 \uacf5\uae09\uc5d0 \ub300\ud55c \uc9c0\uc815\ud559\uc801 \uac10\uc2dc \uac15\ud654 \ub610\ud55c \uc2dc\uc7a5\uc5d0 \uc81c\uc57d\uc73c\ub85c \uc791\uc6a9\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\ubcf8 \ubcf4\uace0\uc11c\ub294 ATMP CDMO \uc2dc\uc7a5\uc744 \uce58\ub8cc \uc720\ud615(\uc720\uc804\uc790 \uce58\ub8cc, \uc138\ud3ec \uce58\ub8cc, \uc870\uc9c1 \uacf5\ud559 \uc81c\ud488, \ubcf5\ud569 ATMP), \uc11c\ube44\uc2a4 \uc720\ud615(\uacf5\uc815 \uac1c\ubc1c, CGMP \uc81c\uc870, \ucda9\uc804-\uc644\uc131 \ubc0f \ud3ec\uc7a5, \ubd84\uc11d \ubc0f \ud488\uc9c8 \uad00\ub9ac \ud14c\uc2a4\ud2b8, \uaddc\uc81c \ubc0f \ud488\uc9c8 \ubcf4\uc99d \uc9c0\uc6d0), \uac1c\ubc1c \ub2e8\uacc4(\uc804\uc784\uc0c1, 1\uc0c1, 2\uc0c1, 3\uc0c1, \uc0c1\uc5c5\ud654), \ubca1\ud130 \uc720\ud615(AAV, \ub80c\ud2f0\ubc14\uc774\ub7ec\uc2a4, \ub808\ud2b8\ub85c\ubc14\uc774\ub7ec\uc2a4 \ubc0f \uac10\ub9c8-\ub808\ud2b8\ub85c\ubc14\uc774\ub7ec\uc2a4, \ube44\ubc14\uc774\ub7ec\uc2a4\/\ud50c\ub77c\uc2a4\ubbf8\ub4dc), \uc138\ud3ec \uacf5\uae09\uc6d0(\uc790\uac00\uc720\ub798, \ub3d9\uc885\uc720\ub798) \ubc0f \uc9c0\uc5ed(\ubd81\ubbf8, \uc720\ub7fd, \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591, \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74, \ub0a8\ubbf8)\ubcc4\ub85c \uc138\ubd84\ud654\ud558\uc5ec \ubd84\uc11d\ud569\ub2c8\ub2e4. \uc804 \uc138\uacc4 \uc8fc\uc694 \uc9c0\uc5ed\uc758 17\uac1c\uad6d\uc5d0 \ub300\ud55c \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \ub3d9\ud5a5\ub3c4 \ub2e4\ub8f9\ub2c8\ub2e4.<\/p>\n<p>\ubcf4\uace0\uc11c\uc5d0 \ub530\ub974\uba74, ATMP CDMO \uc2dc\uc7a5\uc740 2031\ub144\uae4c\uc9c0 \uc5f0\ud3c9\uade0 24.4%\uc758 \ub450 \uc790\ub9bf\uc218 \uc131\uc7a5\uc744 \uae30\ub85d\ud560 \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4. \uc774\ub294 FDA \ubc0f EMA \uc2b9\uc778 \uc138\ud3ec \ubc0f \uc720\uc804\uc790 \uce58\ub8cc\uc81c \ud30c\uc774\ud504\ub77c\uc778\uc758 \ud655\ub300\uc640 CMC(Chemistry, Manufacturing, and Controls) \uc5c5\ubb34\uc758 \ucd08\uae30 \uc544\uc6c3\uc18c\uc2f1 \uc99d\uac00\uc5d0 \uae30\uc778\ud569\ub2c8\ub2e4. \ud2b9\ud788, \uaddc\uc81c \ubc0f \ud488\uc9c8 \ubcf4\uc99d \uc9c0\uc6d0 \uc11c\ube44\uc2a4\ub294 \ub2e4\uc591\ud55c \uae00\ub85c\ubc8c \uc11c\ub958 \uc694\uad6c\uc0ac\ud56d\uc5d0 \ub300\ud55c \uc2a4\ud3f0\uc11c\ub4e4\uc758 \ub300\uc751 \ud544\uc694\uc131\uc73c\ub85c \uc778\ud574 \uc5f0\ud3c9\uade0 26.87%\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud558\ub294 \uc11c\ube44\uc2a4 \ub77c\uc778\uc73c\ub85c \ubd80\uc0c1\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc9c0\uc5ed\ubcc4\ub85c\ub294 \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591 \uc9c0\uc5ed\uc774 \uc5f0\ud3c9\uade0 25.76%\ub85c \ubaa8\ub4e0 \uc9c0\uc5ed\uc744 \ub2a5\uac00\ud558\ub294 \uc131\uc7a5\uc138\ub97c \ubcf4\uc774\uba70, \uc608\uce21 \uae30\uac04 \ub9d0\uae4c\uc9c0 \ubd81\ubbf8\uc640\uc758 \uaca9\ucc28\ub97c \ud06c\uac8c \uc904\uc77c \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. \ud3d0\uc1c4\ud615 \ubaa8\ub4c8\uc2dd \uc2a4\uc704\ud2b8\ub294 \uc644\uc804 \uc790\ub3d9\ud654 \uc2dc\uc2a4\ud15c\uc744 \ud1b5\ud574 &#8216;Vein-to-Vein&#8217; \uc2dc\uac04\uc744 1\uc8fc\uc77c \ubbf8\ub9cc\uc73c\ub85c \ub2e8\ucd95\ud558\uace0 \uc624\uc5fc \uc704\ud5d8\uc744 \uc904\uc5ec \uc790\uac00\uc720\ub798 CAR-T \uc0dd\uc0b0\uc5d0 \ub9e4\ub825\uc801\uc778 \ub300\uc548\uc73c\ub85c \uc8fc\ubaa9\ubc1b\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uadf8\ub7ec\ub098 GMP \ub4f1\uae09 \ud50c\ub77c\uc2a4\ubbf8\ub4dc DNA \uacf5\uae09\uc740 \uc804 \uc138\uacc4\uc801\uc73c\ub85c \ud0ac\ub85c\uadf8\ub7a8 \uaddc\ubaa8 \uacf5\uae09\uc5c5\uccb4\uac00 \uc81c\ud55c\uc801\uc774\uc5b4\uc11c 9-12\uac1c\uc6d4\uc5d0 \uc774\ub974\ub294 \ub9ac\ub4dc \ud0c0\uc784\uc73c\ub85c \uc778\ud574 \uacf5\uae09 \uc5f0\uc18d\uc131\uc744 \uc704\ud611\ud558\ub294 \uc8fc\uc694 \uae30\uc220 \ubcd1\ubaa9 \ud604\uc0c1\uc73c\ub85c \uc9c0\uc801\ub429\ub2c8\ub2e4.<\/p>\n<p>\uacbd\uc7c1 \ud658\uacbd \ubd84\uc11d \uc139\uc158\uc5d0\uc11c\ub294 \uc2dc\uc7a5 \uc9d1\uc911\ub3c4, \uc2dc\uc7a5 \uc810\uc720\uc728 \ubd84\uc11d \ubc0f \uc8fc\uc694 \uae30\uc5c5 \ud504\ub85c\ud544\uc744 \uc81c\uacf5\ud569\ub2c8\ub2e4. \uc8fc\uc694 \uae30\uc5c5\uc73c\ub85c\ub294 Lonza Group Ltd., Catalent Inc., Samsung Biologics Co., Ltd., Thermo Fisher Scientific Inc., WuXi AppTec Co., Ltd. \ub4f1\uc774 \ud3ec\ud568\ub429\ub2c8\ub2e4. \ub9c8\uc9c0\ub9c9\uc73c\ub85c, \ubcf4\uace0\uc11c\ub294 \uc2dc\uc7a5 \uae30\ud68c\uc640 \ubbf8\ub798 \uc804\ub9dd, \uadf8\ub9ac\uace0 \ubbf8\ucda9\uc871 \uc218\uc694\uc5d0 \ub300\ud55c \ud3c9\uac00\ub97c \uc81c\uc2dc\ud569\ub2c8\ub2e4.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-46040","post","type-post","status-publish","format-standard","hentry","category-market-reports"],"_links":{"self":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts\/46040"}],"collection":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/comments?post=46040"}],"version-history":[{"count":0,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts\/46040\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/media?parent=46040"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/categories?post=46040"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/tags?post=46040"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}